{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:42:40Z","timestamp":1762652560551,"version":"build-2065373602"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"am","delay-in-days":282,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32DA007233"],"award-info":[{"award-number":["T32DA007233"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.josat.2024.209308","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T04:58:09Z","timestamp":1706590689000},"page":"209308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Prevalence and associated risk factors of hepatitis C antibody and RNA among people who inject drugs in Puerto Rico"],"prefix":"10.1016","volume":"160","author":[{"given":"Yesenia","family":"Aponte-Mel\u00e9ndez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Eckhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunki","family":"Fong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanda","family":"Trinidad-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Maldonado-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Agront","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Mateu-Gelabert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.josat.2024.209308_bb0005","doi-asserted-by":"crossref","DOI":"10.1186\/s12954-020-00421-z","article-title":"\u201cCaballo\u201d: Risk environments, drug sharing and the emergence of a hepatitis C virus epidemic among people who inject drugs in Puerto Rico","volume":"17","author":"Abadie","year":"2020","journal-title":"Harm Reduction Journal"},{"issue":"1","key":"10.1016\/j.josat.2024.209308_bb0010","doi-asserted-by":"crossref","DOI":"10.1186\/s12954-016-0099-9","article-title":"Understanding differences in HIV\/HCV prevalence according to differentiated risk behaviors in a sample of PWID in rural Puerto Rico","volume":"13","author":"Abadie","year":"2016","journal-title":"Harm Reduction Journal"},{"issue":"9","key":"10.1016\/j.josat.2024.209308_bb0015","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1007\/s10461-013-0593-y","article-title":"Effectiveness of structural-level needle\/syringe programs to reduce HCV and HIV infection among people who inject drugs: A systematic review","volume":"17","author":"Abdul-Quader","year":"2013","journal-title":"AIDS and Behavior"},{"author":"Administraci\u00f3n de Seguros de Salud","key":"10.1016\/j.josat.2024.209308_bb0020"},{"key":"10.1016\/j.josat.2024.209308_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103247","article-title":"Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis","volume":"96","author":"Amoako","year":"2021","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.josat.2024.209308_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.dadr.2023.100178","article-title":"Hepatitis C virus care cascade among people who inject drugs in Puerto Rico: Minimal HCV treatment and substantial barriers to HCV care","volume":"8","author":"Aponte-Mel\u00e9ndez","year":"2023","journal-title":"Drug and Alcohol Dependence Reports"},{"key":"10.1016\/j.josat.2024.209308_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108684","article-title":"Health care-seeking experiences for people who inject drugs with hepatitis C: Qualitative explorations of stigma","volume":"137","author":"Austin","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"6","key":"10.1016\/j.josat.2024.209308_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179931","article-title":"Risk factors for prevalent hepatitis C virus-infection among inmates in a state prison system in Mexico","volume":"12","author":"Belaunzar\u00e1n-Zamudio","year":"2017","journal-title":"PLoS One"},{"issue":"suppl_2","key":"10.1016\/j.josat.2024.209308_bb0045","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1093\/cid\/cit271","article-title":"Models of care for the management of hepatitis C virus among people who inject drugs: One size does not fit all","volume":"57","author":"Bruggmann","year":"2013","journal-title":"Clinical Infectious Diseases"},{"author":"Center for Health Law and Policy Innovation","key":"10.1016\/j.josat.2024.209308_bb0050"},{"key":"10.1016\/j.josat.2024.209308_bb0055","series-title":"National HIV behavioral surveillance system persons who inject drugs cycle 5 2018","article-title":"Prevalence and risk factors associated with Hepatitis C: A cross-sectional study using data from the Puerto Rico","author":"Col\u00f3n-L\u00f3pez","year":"2022"},{"issue":"5","key":"10.1016\/j.josat.2024.209308_bb0060","doi-asserted-by":"crossref","first-page":"e659","DOI":"10.1016\/S2214-109X(23)00057-8","article-title":"Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: A systematic review","volume":"11","author":"Degenhardt","year":"2023","journal-title":"The Lancet Global Health"},{"issue":"5","key":"10.1016\/j.josat.2024.209308_bb0065","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/00126334-200408150-00010","article-title":"HIV incidence among high-risk Puerto Rican drug users: A comparison of East Harlem, New York, and Bayamon, Puerto Rico","volume":"36","author":"Deren","year":"2004","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.josat.2024.209308_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101148","article-title":"Outcomes of real-world integrated HCV microelimination for people who inject drugs: An expansion of the Punjab Model","volume":"41","author":"Dhiman","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.josat.2024.209308_bb0075","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/infdis\/jis677","article-title":"Transmission of hepatitis C virus among people who inject drugs: Viral stability and association with drug preparation equipment","volume":"207","author":"Doerrbecker","year":"2013","journal-title":"The Journal of Infectious Diseases"},{"issue":"5","key":"10.1016\/j.josat.2024.209308_bb0080","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1001\/jamainternmed.2022.0170","article-title":"Accessible hepatitis C care for people who inject drugs: A randomized clinical trial","volume":"182","author":"Eckhardt","year":"2022","journal-title":"JAMA Internal Medicine"},{"issue":"5","key":"10.1016\/j.josat.2024.209308_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177341","article-title":"Risk factors for hepatitis C seropositivity among young people who inject drugs in new York City: Implications for prevention","volume":"12","author":"Eckhardt","year":"2017","journal-title":"PLoS One"},{"issue":"SI2","key":"10.1016\/j.josat.2024.209308_bb0090","first-page":"141","article-title":"Exploring the influence of social determinants on HIV risk behaviors and the potential application of structural interventions to prevent HIV in women","volume":"7","author":"Edwards","year":"2014","journal-title":"Journal of Health Disparities Research and Practice"},{"key":"10.1016\/j.josat.2024.209308_bb0095","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1023\/A:1026498321919","article-title":"Syringe acquisition and use of syringe exchange programs by Puerto Rican drug injectors in New York and Puerto Rico: Comparisons based on quantitative and qualitative methods","volume":"4","author":"Finlinson","year":"2000","journal-title":"AIDS and Behavior"},{"issue":"9","key":"10.1016\/j.josat.2024.209308_bb0100","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/10826080600885092","article-title":"A longitudinal study of syringe acquisition by Puerto Rican injection drug users in New York and Puerto Rico: Implications for syringe exchange and distribution programs","volume":"41","author":"Finlinson","year":"2006","journal-title":"Substance Use & Misuse"},{"key":"10.1016\/j.josat.2024.209308_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108589","article-title":"Medical provider stigma experienced by people who use drugs (MPS-PWUD): Development and validation of a scale among people who currently inject drugs in New York City","volume":"221","author":"Fong","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2024.209308_bb0110","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.drugpo.2019.03.016","article-title":"Injection risk norms and practices among migrant Puerto Rican people who inject drugs in New York City: The limits of acculturation theory","volume":"69","author":"Gelp\u00ed-Acosta","year":"2019","journal-title":"International Journal of Drug Policy"},{"issue":"1","key":"10.1016\/j.josat.2024.209308_bb0115","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/0091450920964576","article-title":"Toward community empowerment: The Puerto Rican ganchero","volume":"48","author":"Gelp\u00ed-Acosta","year":"2021","journal-title":"Contemporary Drug Problems"},{"issue":"3","key":"10.1016\/j.josat.2024.209308_bb0120","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","article-title":"Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): An open-label, single-arm, phase 4, multicentre trial","volume":"3","author":"Grebely","year":"2018","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"5","key":"10.1016\/j.josat.2024.209308_bb0125","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/infdis\/jiq111","article-title":"Prevention of hepatitis C virus in injecting drug users: A narrow window of opportunity","volume":"203","author":"Grebely","year":"2011","journal-title":"Journal of Infectious Diseases"},{"issue":"2\u20133","key":"10.1016\/j.josat.2024.209308_bb0130","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.drugalcdep.2009.09.015","article-title":"Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study","volume":"107","author":"Grebely","year":"2010","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.josat.2024.209308_bb0135","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2893.2009.01080.x","article-title":"Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner-city residents","volume":"16","author":"Grebely","year":"2009","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1016\/j.josat.2024.209308_bb0140","first-page":"111","article-title":"High prevalence of hepatitis C infection in a Brazilian prison: Identification of risk factors for infection","volume":"5","author":"Guimar\u00e3es","year":"2001","journal-title":"Brazilian Journal of Infectious Diseases"},{"issue":"1","key":"10.1016\/j.josat.2024.209308_bb0145","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2105\/AJPH.91.1.42","article-title":"Sharing of drug preparation equipment as a risk factor for hepatitis C","volume":"91","author":"Hagan","year":"2001","journal-title":"American Journal of Public Health"},{"issue":"11","key":"10.1016\/j.josat.2024.209308_bb0150","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1086\/345554","article-title":"Hepatitis C virus seroconversion among young injection drug users: Relationships and risks","volume":"186","author":"Hahn","year":"2002","journal-title":"The Journal of Infectious Diseases"},{"issue":"1","key":"10.1016\/j.josat.2024.209308_bb0155","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1477-7517-10-7","article-title":"Hepatitis C treatment access and uptake for people who inject drugs: A review mapping the role of social factors","volume":"10","author":"Harris","year":"2013","journal-title":"Harm Reduction Journal"},{"issue":"4","key":"10.1016\/j.josat.2024.209308_bb0160","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep4.1307","article-title":"Effectiveness of ledipasvir\/sofosbuvir and sofosbuvir\/velpatasvir in people who inject drugs and\/or those in opioid agonist therapy","volume":"3","author":"Janjua","year":"2019","journal-title":"Hepatology Communications"},{"issue":"1","key":"10.1016\/j.josat.2024.209308_bb0165","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12954-023-00831-9","article-title":"\u201cTreated like a human being\u201d: Perspectives of people who inject drugs attending low-threshold HCV treatment at a syringe service program in New York City","volume":"20","author":"Kapadia","year":"2023","journal-title":"Harm Reduction Journal"},{"key":"10.1016\/j.josat.2024.209308_bb0170","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1478-3231.2011.02538.x","article-title":"Trends and projections of hepatitis C virus epidemiology in Latin America","volume":"31","author":"Kershenobich","year":"2011","journal-title":"Liver International"},{"issue":"8","key":"10.1016\/j.josat.2024.209308_bb0175","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.cgh.2018.10.045","article-title":"Disparate trends in mortality of etiology-specific chronic liver diseases among Hispanic subpopulations","volume":"17","author":"Kim","year":"2019","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"4","key":"10.1016\/j.josat.2024.209308_bb0180","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3138\/canlivj.2019-0007","article-title":"Hepatitis C virus (HCV) care in Canadian correctional facilities: Where are we and where do we need to be?","volume":"2","author":"Kronfli","year":"2019","journal-title":"Canadian Liver Journal"},{"issue":"12","key":"10.1016\/j.josat.2024.209308_bb0185","doi-asserted-by":"crossref","first-page":"e1208","DOI":"10.1016\/S2214-109X(17)30373-X","article-title":"Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: A systematic review","volume":"5","author":"Larney","year":"2017","journal-title":"The Lancet Global Health"},{"issue":"1","key":"10.1016\/j.josat.2024.209308_bb0190","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/MEG.0b013e328340c451","article-title":"Hepatitis C testing and treatment among active drug users in Amsterdam: Results from the DUTCH-C project","volume":"23","author":"Lindenburg","year":"2011","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"10.1016\/j.josat.2024.209308_bb0195","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s10900-007-9083-3","article-title":"Limited uptake of hepatitis C treatment among injection drug users","volume":"33","author":"Mehta","year":"2008","journal-title":"Journal of Community Health"},{"issue":"4","key":"10.1016\/j.josat.2024.209308_bb0200","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/1545109710397768","article-title":"HIV and drug use in Puerto Rico: Findings from the ARIBBA study","volume":"10","author":"Mino","year":"2011","journal-title":"Journal of the International Association of Physicians in AIDS Care"},{"issue":"5","key":"10.1016\/j.josat.2024.209308_bb0205","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1080\/10826084.2021.1892142","article-title":"Acceptability and effectiveness of hepatitis C care at syringe service programs for people who inject drugs in New York City","volume":"56","author":"Muncan","year":"2021","journal-title":"Substance Use & Misuse"},{"author":"National Minority AIDS Council","key":"10.1016\/j.josat.2024.209308_bb0210"},{"issue":"7","key":"10.1016\/j.josat.2024.209308_bb0215","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1086\/656212","article-title":"Survival of hepatitis C virus in syringes: Implication for transmission among injection drug users","volume":"202","author":"Paintsil","year":"2010","journal-title":"The Journal of Infectious Diseases"},{"issue":"4","key":"10.1016\/j.josat.2024.209308_bb0220","article-title":"Hepatitis C in Puerto Rico: A time for public health action","volume":"26","author":"P\u00e9rez","year":"2007","journal-title":"Puerto Rico Health Sciences Journal"},{"issue":"3","key":"10.1016\/j.josat.2024.209308_bb0225","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/add.14012","article-title":"Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: Findings from a Cochrane review and meta-analysis","volume":"113","author":"Platt","year":"2018","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.josat.2024.209308_bb0230","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1360-0443.2011.03765.x","article-title":"Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment","volume":"107","author":"Pouget","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.josat.2024.209308_bb0235","series-title":"APHA 139th annual meeting and exposition, Washington, DC","article-title":"Housing instability and hepatitis C seroconversion among injection drug users: A meta-analytic review","volume":"2011","author":"Pouget","year":"2011"},{"issue":"6","key":"10.1016\/j.josat.2024.209308_bb0240","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s11524-006-9109-7","article-title":"Prevalence and correlates of hepatitis C virus infection among street-recruited injection drug users in San Juan, Puerto Rico","volume":"83","author":"Reyes","year":"2006","journal-title":"Journal of Urban Health"},{"issue":"3","key":"10.1016\/j.josat.2024.209308_bb0245","article-title":"Social determinants of health associated with hepatitis C co-infection among people living with HIV: Results from the Positive Spaces, Healthy Places study","volume":"5","author":"Rourke","year":"2011","journal-title":"Open Medicine"},{"issue":"3","key":"10.1016\/j.josat.2024.209308_bb0250","doi-asserted-by":"crossref","first-page":"134","DOI":"10.24875\/AIDSRev.M17000006","article-title":"HIV and HCV in US prisons and jails: The correctional facility as a bellwether over time for the community\u2019s infections","volume":"19","author":"Spaulding","year":"2017","journal-title":"AIDS Reviews"},{"key":"10.1016\/j.josat.2024.209308_bb0255","first-page":"81","article-title":"The global state of harm reduction","volume":"6","author":"Stone","year":"2018","journal-title":"Harm Reduction International"},{"issue":"s5","key":"10.1016\/j.josat.2024.209308_bb0260","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1086\/427445","article-title":"Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users","volume":"40","author":"Strathdee","year":"2005","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"10.1016\/j.josat.2024.209308_bb0265","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression","volume":"48","author":"Thein","year":"2008","journal-title":"Hepatology"},{"author":"United States Department of Health and Human Services Office of Minority Health","key":"10.1016\/j.josat.2024.209308_bb0270"},{"key":"10.1016\/j.josat.2024.209308_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103930","article-title":"How the rural risk environment underpins hepatitis C risk: Qualitative findings from rural southern Illinois, United States","volume":"112","author":"Walters","year":"2023","journal-title":"International Journal of Drug Policy"},{"author":"White House Office of National AIDS Policy","key":"10.1016\/j.josat.2024.209308_bb0280"},{"issue":"1","key":"10.1016\/j.josat.2024.209308_bb0285","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jnma.2015.12.004","article-title":"A systematic review of race and ethnicity in hepatitis C clinical trial enrollment","volume":"108","author":"Wilder","year":"2016","journal-title":"Journal of the National Medical Association"},{"key":"10.1016\/j.josat.2024.209308_bb0290","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jsat.2019.04.009","article-title":"Influence of social determinants of health and substance use characteristics on persons who use drugs pursuit of care for hepatitis C virus infection","volume":"102","author":"Williams","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209308_bb0295","unstructured":"World Health Organization. Global HIV, hepatitis and STIs programmes: People who inject drugs. World Health Organization. https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/populations\/people-who-inject-drugs."},{"year":"1984","series-title":"Drug, set, setting: The basis for controlled intoxicant use","author":"Zinberg","key":"10.1016\/j.josat.2024.209308_bb0300"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875924000201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875924000201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:40:43Z","timestamp":1762652443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875924000201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":60,"alternative-id":["S2949875924000201"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2024.209308","relation":{},"ISSN":["2949-8759"],"issn-type":[{"type":"print","value":"2949-8759"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and associated risk factors of hepatitis C antibody and RNA among people who inject drugs in Puerto Rico","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2024.209308","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"209308"}}